{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:05:23Z","timestamp":1779293123753,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"DOI":"10.7759\/cureus.91677","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:26:51Z","timestamp":1757093211000},"source":"Crossref","is-referenced-by-count":1,"title":["Medical vs. Surgical Obesity Management: A Narrative Review of Efficacy, Safety, and Long-Term Outcomes"],"prefix":"10.7759","author":[{"given":"Joyce","family":"Akwe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimela","family":"Fongeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann Kirkconnell","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viniya","family":"Patidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo Mee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO. Fact Sheet. Obesity and Overweight. (2025). Accessed: August 27, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68376","article-title":"Trends and patterns in obesity-related deaths in the US (2010-2020): A comprehensive analysis using Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Data","volume":"16","author":"Achara KE","year":"2024","unstructured":"Achara KE, Iyayi IR, Erinne OC, et al.. Trends and patterns in obesity-related deaths in the US (2010-2020): A comprehensive analysis using Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Data. Cureus. 2024, 16:e68376. 10.7759\/cureus.68376","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald E","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, et al.. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022, 163:1198-225. 10.1053\/j.gastro.2022.08.045","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: A review","volume":"330","author":"Elmaleh-Sachs A","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: A review. JAMA. 2023, 330:2000-15. 10.1001\/jama.2023.19897","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff AM","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, et al.. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025, 392:958-71. 10.1056\/NEJMoa2410819","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.66500","article-title":"Long-term effectiveness and outcomes of bariatric surgery: A comprehensive review of current evidence and emerging trends","volume":"16","author":"Ram Sohan P","year":"2024","unstructured":"Ram Sohan P, Mahakalkar C, Kshirsagar S, Bikkumalla S, Reddy S, Hatewar A, Dixit S. Long-term effectiveness and outcomes of bariatric surgery: A comprehensive review of current evidence and emerging trends. Cureus. 2024, 16:e66500. 10.7759\/cureus.66500","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57724-5","article-title":"Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: A systematic review and meta-analysis","volume":"14","author":"Pipek LZ","year":"2024","unstructured":"Pipek LZ, Moraes WA, Nobetani RM, et al.. Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: A systematic review and meta-analysis. Sci Rep. 2024, 14:9521. 10.1038\/s41598-024-57724-5","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo CM","year":"2023","unstructured":"Perdomo CM, Cohen RV, Sumithran P, Cl\u00e9ment K, Fr\u00fchbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023, 401:1116-30. 10.1016\/s0140-6736(22)02403-5","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20660","article-title":"Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults","volume":"22 Suppl 2","author":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","year":"2014","unstructured":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel. Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring). 2014, 22 Suppl 2:S41-410. 10.1002\/oby.20660","journal-title":"Obesity (Silver Spring)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.039453","article-title":"Lifestyle modification for obesity: New developments in diet, physical activity, and behavior therapy","volume":"125","author":"Wadden TA","year":"2012","unstructured":"Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: New developments in diet, physical activity, and behavior therapy. Circulation. 2012, 125:1157-70. 10.1161\/CIRCULATIONAHA.111.039453","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-073763","article-title":"Mediterranean diet and time-restricted eating as a cardiac rehabilitation approach for patients with coronary heart disease and pre-diabetes: The DIABEPIC-1 protocol of a feasibility trial","volume":"13","author":"Iglesies-Grau J","year":"2023","unstructured":"Iglesies-Grau J, Dionne V, Latour \u00c9, et al.. Mediterranean diet and time-restricted eating as a cardiac rehabilitation approach for patients with coronary heart disease and pre-diabetes: The DIABEPIC-1 protocol of a feasibility trial. BMJ Open. 2023, 13:e073763. 10.1136\/bmjopen-2023-073763","journal-title":"BMJ Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy KL","year":"2018","unstructured":"Piercy KL, Troiano RP, Ballard RM, et al.. The physical activity guidelines for Americans. JAMA. 2018, 320:2020-8. 10.1001\/jama.2018.14854","journal-title":"JAMA"},{"key":"ref14","article-title":"Obesity in adults: Drug therapy","author":"Perreault L","year":"2025","unstructured":"Perreault L, Reid T. Obesity in adults: Drug therapy. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref15","article-title":"Tirzepatide: Drug information","year":"2025","unstructured":"Tirzepatide. Drug information. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living\u00a0with overweight or obesity: A systematic review and meta-analysis","volume":"79","author":"Liu L","year":"2025","unstructured":"Liu L, Li Z, Ye W, et al.. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living\u00a0with overweight or obesity: A systematic review and meta-analysis. EClinicalMedicine. 2025, 79:103020. 10.1016\/j.eclinm.2024.103020","journal-title":"EClinicalMedicine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.09.004","article-title":"Charting new territories in obesity management - Traditional techniques to tirzepatide","volume":"31","author":"Fareed A","year":"2025","unstructured":"Fareed A, Ghanem L, Vaid R, Iftikhar Z, Ur Rehman A, Sarwar A, Asif MI. Charting new territories in obesity management - Traditional techniques to tirzepatide. Endocr Pract. 2025, 31:102-13. 10.1016\/j.eprac.2024.09.004","journal-title":"Endocr Pract"},{"key":"ref18","article-title":"Semaglutide: Drug information","year":"2025","unstructured":"Semaglutide. Drug information. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial","volume":"327","author":"Rubino DM","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al.. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022, 327:138-50. 10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"ref20","article-title":"Liraglutide: Drug information","year":"2025","unstructured":"Liraglutide. Drug information. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: The BARI-OPTIMISE randomized clinical trial","volume":"158","author":"Mok J","year":"2023","unstructured":"Mok J, Adeleke MO, Brown A, et al.. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: The BARI-OPTIMISE randomized clinical trial. JAMA Surg. 2023, 158:1003-11. 10.1001\/jamasurg.2023.2930","journal-title":"JAMA Surg"},{"key":"ref22","article-title":"Naltrexone and bupropion: Drug information","year":"2025","unstructured":"Naltrexone and bupropion. Drug information. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S55587","article-title":"Naltrexone sustained-release\/bupropion sustained-release for the management of obesity: Review of the data to date","volume":"8","author":"Caix\u00e0s A","year":"2014","unstructured":"Caix\u00e0s A, Albert L, Capel I, Rigla M. Naltrexone sustained-release\/bupropion sustained-release for the management of obesity: Review of the data to date. Drug Des Devel Ther. 2014, 8:1419-27. 10.2147\/DDDT.S55587","journal-title":"Drug Des Devel Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian CM","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, et al.. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013, 21:935-43. 10.1002\/oby.20309","journal-title":"Obesity (Silver Spring)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: A randomized clinical trial","volume":"315","author":"Nissen SE","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, et al.. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: A randomized clinical trial. JAMA. 2016, 315:990-1004. 10.1001\/jama.2016.1558","journal-title":"JAMA"},{"key":"ref26","article-title":"Phentermine and topiramate: Drug information","year":"2025","unstructured":"Phentermine and topiramate. Drug information. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: A randomized controlled trial (EQUIP)","volume":"20","author":"Allison DB","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, et al.. Controlled-release phentermine\/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012, 20:330-42. 10.1038\/oby.2011.330","journal-title":"Obesity (Silver Spring)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde KM","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377:1341-52. 10.1016\/s0140-6736(11)60205-5","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study","volume":"381","author":"Buse JB","year":"2013","unstructured":"Buse JB, Nauck M, Forst T, et al.. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study. Lancet. 2013, 381:117-24. 10.1016\/s0140-6736(12)61267-7","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias JP","year":"2021","unstructured":"Frias JP, Bonora E, Nevarez Ruiz L, et al.. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021, 44:765-73. 10.2337\/dc20-1473","journal-title":"Diabetes Care"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock J","year":"2013","unstructured":"Rosenstock J, Raccah D, Kor\u00e1nyi L, Maffei L, Boka G, Miossec P, Gerich JE. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013, 36:2945-51. 10.2337\/dc12-2709","journal-title":"Diabetes Care"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau DCW","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021, 398:2160-72. 10.1016\/s0140-6736(21)01751-7","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley RE","year":"2014","unstructured":"Pratley RE, Nauck MA, Barnett AH, et al.. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014, 2:289-97. 10.1016\/s2213-8587(13)70214-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.124","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects","volume":"33","author":"Cercato C","year":"2009","unstructured":"Cercato C, Roizenblatt VA, Lean\u00e7a CC, Segal A, Lopes Filho AP, Mancini MC, Halpern A. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond). 2009, 33:857-65. 10.1038\/ijo.2009.124","journal-title":"Int J Obes (Lond)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039908","article-title":"Combination of diethylpropion with dietary intervention results in body weight and fat loss with preserved muscle mass in obese patients","volume":"103","author":"Nugraha GI","year":"2024","unstructured":"Nugraha GI, Amalia F, Imadudda'wah F, Ariyanto EF, Ghozali M, Fatimah SN. Combination of diethylpropion with dietary intervention results in body weight and fat loss with preserved muscle mass in obese patients. Medicine (Baltimore). 2024, 103:e39908. 10.1097\/MD.0000000000039908","journal-title":"Medicine (Baltimore)"},{"key":"ref36","article-title":"Diethylpropion: Drug information","year":"2025","unstructured":"Diethylpropion. Drug information. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-025-01729-1","article-title":"Role of pancreatic lipase inhibition in obesity treatment: Mechanisms and challenges towards current insights and future directions","volume":"49","author":"Subramaniyan V","year":"2025","unstructured":"Subramaniyan V, Hanim YU. Role of pancreatic lipase inhibition in obesity treatment: Mechanisms and challenges towards current insights and future directions. Int J Obes (Lond). 2025, 49:492-506. 10.1038\/s41366-025-01729-1","journal-title":"Int J Obes (Lond)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-025-01719-3","article-title":"Association of long-term weight management pharmacotherapy with multiple health outcomes: An umbrella review and evidence map","volume":"49","author":"Lu TT","year":"2025","unstructured":"Lu TT, Liu B, Ge L, Liu YL, Lu Y. Association of long-term weight management pharmacotherapy with multiple health outcomes: An umbrella review and evidence map. Int J Obes (Lond). 2025, 49:464-77. 10.1038\/s41366-025-01719-3","journal-title":"Int J Obes (Lond)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker DJ","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025, 24:631-50. 10.1038\/s41573-025-01183-8","journal-title":"Nat Rev Drug Discov"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies MJ","year":"2025","unstructured":"Davies MJ, Bajaj HS, Broholm C, et al.. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. 2025, 393:648-59. 10.1056\/NEJMoa2502082","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey WT","year":"2025","unstructured":"Garvey WT, Bl\u00fcher M, Osorto Contreras CK, et al.. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025, 393:635-47. 10.1056\/NEJMoa2502081","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2472408","article-title":"The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: A look at phase 2 and 3 pipelines","volume":"34","author":"Madsbad S","year":"2025","unstructured":"Madsbad S, Holst JJ. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: A look at phase 2 and 3 pipelines. Expert Opin Investig Drugs. 2025, 34:197-215. 10.1080\/13543784.2025.2472408","journal-title":"Expert Opin Investig Drugs"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: Do we need approaches to preserve muscle mass?","author":"Ryan DH","year":"2025","unstructured":"Ryan DH. New drugs for the treatment of obesity: Do we need approaches to preserve muscle mass?. Rev Endocr Metab Disord. 2025, 10.1007\/s11154-025-09967-4","journal-title":"Rev Endocr Metab Disord"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: An Endocrine Society clinical practice guideline","volume":"100","author":"Apovian CM","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH, et al.. Pharmacological management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015, 100:342-62. 10.1210\/jc.2014-3415","journal-title":"J Clin Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield J","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, et al.. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial. Lancet. 2024, 404:773-86. 10.1016\/s0140-6736(24)01498-3","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001214","article-title":"Advances in the management of obesity and heart failure: Latest evidence from clinical trials","volume":"40","author":"Costa TA","year":"2025","unstructured":"Costa TA, Harrington JL. Advances in the management of obesity and heart failure: Latest evidence from clinical trials. Curr Opin Cardiol. 2025, 40:164-71. 10.1097\/HCO.0000000000001214","journal-title":"Curr Opin Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s13030-020-00177-9","article-title":"Personalized cognitive-behavioural therapy for obesity (CBT-OB): Theory, strategies and procedures","volume":"14","author":"Dalle Grave R","year":"2020","unstructured":"Dalle Grave R, Sartirana M, Calugi S. Personalized cognitive-behavioural therapy for obesity (CBT-OB): Theory, strategies and procedures. Biopsychosoc Med. 2020, 14:5. 10.1186\/s13030-020-00177-9","journal-title":"Biopsychosoc Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63881","article-title":"Revolutionizing healthcare: How telemedicine is improving patient outcomes and expanding access to care","volume":"16","author":"Ezeamii VC","year":"2024","unstructured":"Ezeamii VC, Okobi OE, Wambai-Sani H, et al.. Revolutionizing healthcare: How telemedicine is improving patient outcomes and expanding access to care. Cureus. 2024, 16:e63881. 10.7759\/cureus.63881","journal-title":"Cureus"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12012","article-title":"Review of the key results from the Swedish Obese Subjects (SOS) trial - A prospective controlled intervention study of bariatric surgery","volume":"273","author":"Sj\u00f6str\u00f6m L","year":"2013","unstructured":"Sj\u00f6str\u00f6m L. Review of the key results from the Swedish Obese Subjects (SOS) trial - A prospective controlled intervention study of bariatric surgery. J Intern Med. 2013, 273:219-34. 10.1111\/joim.12012","journal-title":"J Intern Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: A review","volume":"324","author":"Arterburn DE","year":"2020","unstructured":"Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: A review. JAMA. 2020, 324:879-87. 10.1001\/jama.2020.12567","journal-title":"JAMA"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2024.01.012","article-title":"American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States","volume":"20","author":"Clapp B","year":"2024","unstructured":"Clapp B, Ponce J, Corbett J, et al.. American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2024, 20:425-31. 10.1016\/j.soard.2024.01.012","journal-title":"Surg Obes Relat Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3525-0","article-title":"Long-term outcomes after bariatric surgery: A systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding","volume":"29","author":"O'Brien PE","year":"2019","unstructured":"O'Brien PE, Hindle A, Brennan L, et al.. Long-term outcomes after bariatric surgery: A systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019, 29:3-14. 10.1007\/s11695-018-3525-0","journal-title":"Obes Surg"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002348","article-title":"Ten-year outcomes of a prospective randomized trial of laparoscopic gastric bypass versus laparoscopic gastric banding","volume":"268","author":"Nguyen NT","year":"2018","unstructured":"Nguyen NT, Kim E, Vu S, Phelan M. Ten-year outcomes of a prospective randomized trial of laparoscopic gastric bypass versus laparoscopic gastric banding. Ann Surg. 2018, 268:106-13. 10.1097\/SLA.0000000000002348","journal-title":"Ann Surg"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2011.10.021","article-title":"Perioperative complications in a consecutive series of 1000 duodenal switches","volume":"9","author":"Biertho L","year":"2013","unstructured":"Biertho L, Lebel S, Marceau S, et al.. Perioperative complications in a consecutive series of 1000 duodenal switches. Surg Obes Relat Dis. 2013, 9:63-8. 10.1016\/j.soard.2011.10.021","journal-title":"Surg Obes Relat Dis"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.14.1724","article-title":"Bariatric surgery: A systematic review and meta-analysis","volume":"292","author":"Buchwald H","year":"2004","unstructured":"Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: A systematic review and meta-analysis. JAMA. 2004, 292:1724-37. 10.1001\/jama.292.14.1724","journal-title":"JAMA"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1381\/096089202321088165","article-title":"Laparoscopic standard biliopancreatic diversion: Technique and preliminary results","volume":"12","author":"Scopinaro N","year":"2002","unstructured":"Scopinaro N, Marinari GM, Camerini G. Laparoscopic standard biliopancreatic diversion: Technique and preliminary results. Obes Surg. 2002, 12:362-5. 10.1381\/096089202321088165","journal-title":"Obes Surg"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2012.07.018","article-title":"Single-anastomosis duodenoileal bypass with sleeve gastrectomy: Metabolic improvement and weight loss in first 100 patients","volume":"9","author":"S\u00e1nchez-Pernaute A","year":"2013","unstructured":"S\u00e1nchez-Pernaute A, Rubio M\u00c1, P\u00e9rez Aguirre E, Barabash A, Cabrerizo L, Torres A. Single-anastomosis duodenoileal bypass with sleeve gastrectomy: Metabolic improvement and weight loss in first 100 patients. Surg Obes Relat Dis. 2013, 9:731-5. 10.1016\/j.soard.2012.07.018","journal-title":"Surg Obes Relat Dis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2011.10.019","article-title":"International Sleeve Gastrectomy Expert Panel Consensus Statement: Best practice guidelines based on experience of >12,000 cases","volume":"8","author":"Rosenthal RJ","year":"2012","unstructured":"Rosenthal RJ, Diaz AA, Arvidsson D, et al.. International Sleeve Gastrectomy Expert Panel Consensus Statement: Best practice guidelines based on experience of >12,000 cases. Surg Obes Relat Dis. 2012, 8:8-19. 10.1016\/j.soard.2011.10.019","journal-title":"Surg Obes Relat Dis"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-05134-7","article-title":"Single anastomosis duodenal-ileal bypass with sleeve gastrectomy\/one anastomosis duodenal switch (SADI-S\/OADS) IFSO position statement-Update 2020","volume":"31","author":"Brown WA","year":"2021","unstructured":"Brown WA, de Leon Ballesteros GP, Ooi G, et al.. Single anastomosis duodenal-ileal bypass with sleeve gastrectomy\/one anastomosis duodenal switch (SADI-S\/OADS) IFSO position statement-Update 2020. Obes Surg. 2021, 31:3-25. 10.1007\/s11695-020-05134-7","journal-title":"Obes Surg"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30475-1","article-title":"Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): A multicentre, randomised, open-label, non-inferiority trial","volume":"393","author":"Robert M","year":"2019","unstructured":"Robert M, Espalieu P, Pelascini E, et al.. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): A multicentre, randomised, open-label, non-inferiority trial. Lancet. 2019, 393:1299-309. 10.1016\/s0140-6736(19)30475-1","journal-title":"Lancet"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51296","article-title":"Single-anastomosis sleeve jejunal bypass as a treatment for morbid obesity: A systematic review and meta-analysis","volume":"15","author":"Alenezi MA","year":"2023","unstructured":"Alenezi MA, Alkhaldi SI, Alrumaih YK, et al.. Single-anastomosis sleeve jejunal bypass as a treatment for morbid obesity: A systematic review and meta-analysis. Cureus. 2023, 15:e51296. 10.7759\/cureus.51296","journal-title":"Cureus"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.106024","article-title":"Systematic review of the outcome of single-anastomosis sleeve ileal (SASI) bypass in treatment of morbid obesity with proportion meta-analysis of improvement in diabetes mellitus","volume":"92","author":"Emile SH","year":"2021","unstructured":"Emile SH, Mahdy T, Schou C, Kramer M, Shikora S. Systematic review of the outcome of single-anastomosis sleeve ileal (SASI) bypass in treatment of morbid obesity with proportion meta-analysis of improvement in diabetes mellitus. Int J Surg. 2021, 92:106024. 10.1016\/j.ijsu.2021.106024","journal-title":"Int J Surg"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-019-07212-z","article-title":"Safety and short-term effectiveness of endoscopic sleeve gastroplasty using overstitch: Preliminary report from a multicenter study","volume":"34","author":"Neto MG","year":"2020","unstructured":"Neto MG, Moon RC, de Quadros LG, et al.. Safety and short-term effectiveness of endoscopic sleeve gastroplasty using overstitch: Preliminary report from a multicenter study. Surg Endosc. 2020, 34:4388-94. 10.1007\/s00464-019-07212-z","journal-title":"Surg Endosc"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1390766","article-title":"Endoscopic sleeve gastroplasty for the treatment of obesity","volume":"47","author":"Lopez-Nava G","year":"2015","unstructured":"Lopez-Nava G, Galv\u00e3o MP, da Bautista-Casta\u00f1o I, Jimenez A, De Grado T, Fernandez-Corbelle JP. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy. 2015, 47:449-52. 10.1055\/s-0034-1390766","journal-title":"Endoscopy"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100112","article-title":"Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings","volume":"11","author":"Gala K","year":"2024","unstructured":"Gala K, Ghusn W, Brunaldi V, et al.. Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings. Obes Pillars. 2024, 11:100112. 10.1016\/j.obpill.2024.100112","journal-title":"Obes Pillars"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-017-2986-x","article-title":"Endoscopic treatment of weight regain following Roux-en-Y gastric bypass: A systematic review and meta-analysis","volume":"28","author":"Brunaldi VO","year":"2018","unstructured":"Brunaldi VO, Jirapinyo P, de Moura DT, et al.. Endoscopic treatment of weight regain following Roux-en-Y gastric bypass: A systematic review and meta-analysis. Obes Surg. 2018, 28:266-76. 10.1007\/s11695-017-2986-x","journal-title":"Obes Surg"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59010125","article-title":"Transoral outlet reduction (TORe) for the treatment of weight regain and Dumping syndrome after Roux-en-Y gastric bypass","volume":"59","author":"Hakiza L","year":"2023","unstructured":"Hakiza L, Sartoretto A, Burgmann K, Kumbhari V, Matter C, Seibold F, Staudenmann D. Transoral outlet reduction (TORe) for the treatment of weight regain and Dumping syndrome after Roux-en-Y gastric bypass. Medicina (Kaunas). 2023, 59:125. 10.3390\/medicina59010125","journal-title":"Medicina (Kaunas)"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5934","article-title":"Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomised controlled trials","volume":"347","author":"Gloy VL","year":"2013","unstructured":"Gloy VL, Briel M, Bhatt DL, et al.. Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomised controlled trials. BMJ. 2013, 347:f5934. 10.1136\/bmj.f5934","journal-title":"BMJ"},{"key":"ref71","article-title":"Pharmacologic treatment of overweight and obesity in adults","author":"Tchang BG","year":"2024","unstructured":"Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic treatment of overweight and obesity in adults. Endotext [Internet]. Feingold KR, Ahmed SF, Anawalt B, et al (ed): MDText.com, Inc, South Dartmouth, MA; 2024."},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-019-04306-4","article-title":"A comprehensive comparison of LRYGB and LSG in obese patients including the effects on QoL, comorbidities, weight loss, and complications: A systematic review and meta-analysis","volume":"30","author":"Hu Z","year":"2020","unstructured":"Hu Z, Sun J, Li R, Wang Z, Ding H, Zhu T, Wang G. A comprehensive comparison of LRYGB and LSG in obese patients including the effects on QoL, comorbidities, weight loss, and complications: A systematic review and meta-analysis. Obes Surg. 2020, 30:819-27. 10.1007\/s11695-019-04306-4","journal-title":"Obes Surg"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.9009","article-title":"Association of bariatric surgery with cancer risk and mortality in adults with obesity","volume":"327","author":"Aminian A","year":"2022","unstructured":"Aminian A, Wilson R, Al-Kurd A, et al.. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022, 327:2423-33. 10.1001\/jama.2022.9009","journal-title":"JAMA"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071027","article-title":"Long term outcomes of metabolic\/bariatric surgery in adults","volume":"383","author":"Courcoulas AP","year":"2023","unstructured":"Courcoulas AP, Daigle CR, Arterburn DE. Long term outcomes of metabolic\/bariatric surgery in adults. BMJ. 2023, 383:e071027. 10.1136\/bmj-2022-071027","journal-title":"BMJ"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa006","article-title":"Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-Year outcomes from a randomized trial","volume":"105","author":"Courcoulas AP","year":"2020","unstructured":"Courcoulas AP, Gallagher JW, Neiberg RH, et al.. Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-Year outcomes from a randomized trial. J Clin Endocrinol Metab. 2020, 105:866-76. 10.1210\/clinem\/dgaa006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14231","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity","volume":"322","author":"Aminian A","year":"2019","unstructured":"Aminian A, Zajichek A, Arterburn DE, et al.. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019, 322:1271-82. 10.1001\/jama.2019.14231","journal-title":"JAMA"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19159078","article-title":"Quality of life after bariatric surgery-A systematic review","volume":"19","author":"Sier\u017cantowicz R","year":"2022","unstructured":"Sier\u017cantowicz R, \u0141adny JR, Lewko J. Quality of life after bariatric surgery-A systematic review. Int J Environ Res Public Health. 2022, 19:9078. 10.3390\/ijerph19159078","journal-title":"Int J Environ Res Public Health"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae888","article-title":"Point-counterpoint debate: Surgery vs medical treatment for the management of obesity","volume":"110","author":"Schauer PR","year":"2025","unstructured":"Schauer PR, Rothberg AE. Point-counterpoint debate: Surgery vs medical treatment for the management of obesity. J Clin Endocrinol Metab. 2025, 110:e1282-7. 10.1210\/clinem\/dgae888","journal-title":"J Clin Endocrinol Metab"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1186\/s40608-015-0041-9","article-title":"Factors associated with participant retention in a clinical, intensive, behavioral weight management program","volume":"2","author":"Rothberg AE","year":"2015","unstructured":"Rothberg AE, McEwen LN, Kraftson AT, et al.. Factors associated with participant retention in a clinical, intensive, behavioral weight management program. BMC Obes. 2015, 2:11. 10.1186\/s40608-015-0041-9","journal-title":"BMC Obes"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003554","article-title":"Changes in utilization of bariatric surgery in the United States from 1993 to 2016","volume":"271","author":"Campos GM","year":"2020","unstructured":"Campos GM, Khoraki J, Browning MG, Pessoa BM, Mazzini GS, Wolfe L. Changes in utilization of bariatric surgery in the United States from 1993 to 2016. Ann Surg. 2020, 271:201-9. 10.1097\/SLA.0000000000003554","journal-title":"Ann Surg"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14215","article-title":"Medical and surgical management of obesity and diabetes: What's new?","volume":"37","author":"Ammori BJ","year":"2020","unstructured":"Ammori BJ, Skarulis MC, Soran H, Syed AA, Eledrisi M, Malik RA. Medical and surgical management of obesity and diabetes: What's new?. Diabet Med. 2020, 37:203-10. 10.1111\/dme.14215","journal-title":"Diabet Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2017.03.025","article-title":"What is the impact on the healthcare system if access to bariatric surgery is delayed?","volume":"13","author":"Cohen RV","year":"2017","unstructured":"Cohen RV, Luque A, Junqueira S, Ribeiro RA, Le Roux CW. What is the impact on the healthcare system if access to bariatric surgery is delayed?. Surg Obes Relat Dis. 2017, 13:1619-27. 10.1016\/j.soard.2017.03.025","journal-title":"Surg Obes Relat Dis"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1177\/00031348231220576","article-title":"Updates in bariatric surgery","volume":"90","author":"Hsu JL","year":"2024","unstructured":"Hsu JL, Farrell TM. Updates in bariatric surgery. Am Surg. 2024, 90:925-33. 10.1177\/00031348231220576","journal-title":"Am Surg"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-024-11191-1","article-title":"A cost comparison of GLP-1 receptor agonists and bariatric surgery: What is the break even point?","volume":"38","author":"Docimo S Jr","year":"2024","unstructured":"Docimo S Jr, Shah J, Warren G, Ganam S, Sujka J, DuCoin C. A cost comparison of GLP-1 receptor agonists and bariatric surgery: What is the break even point?. Surg Endosc. 2024, 38:6560-5. 10.1007\/s00464-024-11191-1","journal-title":"Surg Endosc"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12889","article-title":"Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines","volume":"20","author":"Semlitsch T","year":"2019","unstructured":"Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A. Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines. Obes Rev. 2019, 20:1218-30. 10.1111\/obr.12889","journal-title":"Obes Rev"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-021-00849-8","article-title":"Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model","volume":"45","author":"Boyers D","year":"2021","unstructured":"Boyers D, Retat L, Jacobsen E, et al.. Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model. Int J Obes (Lond). 2021, 45:2179-90. 10.1038\/s41366-021-00849-8","journal-title":"Int J Obes (Lond)"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-016-2271-4","article-title":"Indications for surgery for obesity and weight-related diseases: Position statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)","volume":"26","author":"De Luca M","year":"2016","unstructured":"De Luca M, Angrisani L, Himpens J, et al.. Indications for surgery for obesity and weight-related diseases: Position statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg. 2016, 26:1659-96. 10.1007\/s11695-016-2271-4","journal-title":"Obes Surg"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31822c9dac","article-title":"First report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass","volume":"254","author":"Hutter MM","year":"2011","unstructured":"Hutter MM, Schirmer BD, Jones DB, Ko CY, Cohen ME, Merkow RP, Nguyen NT. First report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg. 2011, 254:410-20; discussion 420-2. 10.1097\/SLA.0b013e31822c9dac","journal-title":"Ann Surg"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002079","article-title":"Prevalence and risk factors for bariatric surgery readmissions: Findings from 130,007 admissions in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program","volume":"267","author":"Berger ER","year":"2018","unstructured":"Berger ER, Huffman KM, Fraker T, et al.. Prevalence and risk factors for bariatric surgery readmissions: Findings from 130,007 admissions in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. Ann Surg. 2018, 267:122-31. 10.1097\/SLA.0000000000002079","journal-title":"Ann Surg"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis","volume":"23","author":"Tsapas A","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, et al.. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2021, 23:2116-24. 10.1111\/dom.14451","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380877-medical-vs-surgical-obesity-management-a-narrative-review-of-efficacy-safety-and-long-term-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:27:01Z","timestamp":1757093221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380877-medical-vs-surgical-obesity-management-a-narrative-review-of-efficacy-safety-and-long-term-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":90,"URL":"https:\/\/doi.org\/10.7759\/cureus.91677","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}